Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein ...
The once-daily oral therapy will be available as treatment for adults with estrogen receptor-positive, human epidermal growth ...
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
On launch, Veppanu will join Menarini/Stemline's Orserdu (elacestrant) and Eli Lilly's Inluriyo (imlunestrant), which were ...
Arvinas’ fair value estimate sits at US$14.88 per share, with the latest model keeping this price target unchanged. That stability comes as Street research remains split, with analysts clustering in ...
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Pfizer Inc. PFE and partner Arvinas Inc. ARVN shares rose Monday after the companies secured a key regulatory win, with the U ...
The FDA approves blood test to guide breast cancer therapy by detecting ESR1 mutations for targeted treatment selection.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a ...
New Haven-based Arvinas Inc. announced it will work with Pfizer Inc. to find a third-party partner to commercialize their jointly developed breast cancer drug candidate, while also cutting jobs and ...
Pfizer (PFE) stock and Arvinas (ARVN) stock are in focus as the FDA approves the companies' breast cancer drug, Veppanu. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results